ethyl (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl)glycinate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl)glycinate
• 英文别名: Ethyl 2-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-pyrazole-3-carbonyl]amino]acetate；ethyl 2-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carbonyl]amino]acetate
• 化学式: C₂₁H₁₈Cl₃N₃O₃
• 分子量: 466.751
• InChiKey: AMEIOFNRZQTNJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  73.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl)glycinate 在 水 作用下， 生成 (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl)glycine
  参考文献：
  名称：

  Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents

  摘要：

  The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.07.009
• 作为产物：
  描述：

  5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl chloride 、 2-胺基乙酸乙酯 在 三乙胺 作用下， 生成 ethyl (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl)glycinate
  参考文献：
  名称：

  CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY

  摘要：

  本发明提供了一种新型吡唑，可作为大麻素受体拮抗剂，并提供了其药物组合物和治疗肥胖、糖尿病和/或心脏代谢紊乱的方法。

  公开号：

  US20070213302A1

文献信息

• Repurposing of a drug scaffold: Identification of novel sila analogues of rimonabant as potent antitubercular agents
  作者：Remya Ramesh、Rahul D. Shingare、Vinod Kumar、Amitesh Anand、Swetha B、Sridhar Veeraraghavan、Srikant Viswanadha、Ramesh Ummanni、Rajesh Gokhale、D. Srinivasa Reddy

  DOI：10.1016/j.ejmech.2016.07.009

  日期：2016.10

  The structural similarity between an MmpL3 inhibitor BM212, and a cannabinoid receptor modulator rimonabant, prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Further optimization, particularly through incorporation of silicon into the scaffold, resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv). The sila analogue 18a was found to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index. (C) 2016 Elsevier Masson SAS. All rights reserved.
• CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING OBESITY
  申请人：McElroy John Francis

  公开号：US20070213302A1

  公开（公告）日：2007-09-13

  The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, and/or cardiometabolic disorders.

  本发明提供了一种新型吡唑，可作为大麻素受体拮抗剂，并提供了其药物组合物和治疗肥胖、糖尿病和/或心脏代谢紊乱的方法。